Maine Clinical Trials Report — April 2026

For Mainers considering participation in clinical research, April 2026 brings a critical reminder of time-sensitive opportunities. Across the state, 6 clinical trials are slated to conclude their enrollment within the next 90 days. This means individuals interested in these specific areas of research must act quickly to explore their eligibility before these studies close to new participants.

These rapidly closing trials are focused on serious health conditions, and none of them are currently accepting healthy volunteers. Patients diagnosed with certain types of cancer, inflammatory bowel disease, or rare genetic disorders will find their window to join these studies narrowing significantly. Conditions with trials nearing their enrollment deadlines include:

• Stage IV lung cancer (AJCC v8)
• Chronic granulomatous disease (CGD)
• Ulcerative colitis
• Endometrial adenocarcinoma (including clear cell, dedifferentiated, endometrioid, mixed cell, and undifferentiated types)
• Advanced lung non-small cell carcinoma

If you or someone you know is living with one of these conditions, it is highly recommended to investigate these opportunities without delay. Participation in these trials could offer access to investigational treatments and contribute valuable data to medical science.

A New Focus on Pancreatic Health in Portland

This month, Maine welcomes a significant new clinical trial, marking the sole addition to the state's research landscape in April 2026. This new study is a Phase 2 drug trial, opening in Portland, and is particularly notable for its focus on pancreatic health and its sponsor, a major industry player.

The trial, NCT07559175, is titled "A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency." Sponsored by Aimmune Nestlé Health Science US R&D, LLC, this study aims to enroll 66 participants to assess the safety and initial effectiveness of a new lipase enzyme, NHS7108. Participants will compare 4 different doses of NHS7108 against a standard-of-care treatment, pancrelipase (Zenpep®), over a 14-day period for each treatment.

This research is crucial for individuals suffering from conditions that lead to Exocrine Pancreatic Insufficiency (EPI), where the pancreas does not produce enough enzymes to digest food properly. The conditions targeted by this study include:

• Cystic fibrosis (CF)
• Exocrine pancreatic insufficiency (EPI)
• Pancreatic diseases
• Pancreatic enzyme abnormality

As a Phase 2 study, this trial represents an important step in drug development, moving beyond initial safety assessments to explore how well the new treatment works. The involvement of Aimmune Nestlé Health Science US R&D, LLC, an industry leader, underscores the potential impact and scientific rigor of this research.

Maine's Research Reach: Where Opportunities Lie

Maine's clinical trial landscape offers a broad array of opportunities, with a total of 198 studies currently recruiting across 28 cities and 108 distinct research sites. While the single new trial this month is located in Portland, the overall distribution of research activity suggests that access to trials is not limited to just one metropolitan area.

Portland, as Maine's largest city, often serves as a hub for medical research, making it a natural location for new studies like the one from Aimmune Nestlé Health Science US R&D, LLC. However, the presence of trials in nearly 30 cities statewide indicates a commitment to making research accessible to a wider population, extending beyond the immediate vicinity of major medical centers.

Participation Insights: Who Can Join and the Healthy Volunteer Landscape

For those considering participation, understanding eligibility is key. The new trial for Exocrine Pancreatic Insufficiency is designed for adult participants and specifically includes older adults, ensuring that this demographic has an opportunity to contribute to the advancement of pancreatic health treatments. This month's new trial does not include children, nor is it exclusively for female or male participants.

While the single new trial opening this month does not accept healthy volunteers, there are still opportunities for individuals without specific medical conditions to contribute to research in Maine. Currently, 10 trials across the state are actively recruiting healthy volunteers. These studies play a vital role in establishing baseline data and understanding how new interventions affect the general population. Individuals interested in supporting medical science without having a specific condition should explore these ongoing options.

A Look at Maine's Clinical Research Trends

The opening of 1 new trial in April 2026 mirrors the activity seen in March 2026, which also saw 1 new study launch. Looking at the past 6 months, the number of new trials opening in Maine has remained relatively consistent and modest, with a peak of 5 new trials in November 2025, followed by 1 new trial in December 2025 and January 2026, and again in March and April 2026. This consistent, albeit lower, rate of new trial openings indicates a steady, focused research effort within the state.

As we move through the spring, the focus for Maine's research community will likely remain on the continued enrollment for the existing 198 trials, particularly those nearing their conclusion, and the progress of the newly launched Phase 2 study in Portland. Future months may bring new opportunities, but for now, the emphasis is on the current, impactful research underway.